{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:07:45Z","timestamp":1784606865605,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00432-017-2556-6","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T06:01:09Z","timestamp":1513404069000},"page":"403-414","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation"],"prefix":"10.1007","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-6995","authenticated-orcid":false,"given":"Franco","family":"Trevisani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Garuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Aurelia","family":"Barbera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casadei Gardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Granito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Lorenzo","family":"Inghilesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovan Giuseppe","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,16]]},"reference":[{"key":"2556_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12032-013-0655-z","volume":"30","author":"O Abdel-Rahman","year":"2013","unstructured":"Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 30:655","journal-title":"Med Oncol"},{"key":"2556_CR2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1177\/548.6527","volume":"96","author":"G Brandi","year":"2010","unstructured":"Brandi G, de Rosa F, Bolondi L, Agostini V, Di Girolamo S, Nobili E, Biasco G (2010) Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori 96:1028\u20131030","journal-title":"Tumori"},{"key":"2556_CR3","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1634\/theoncologist.2013-0093","volume":"18","author":"G Brandi","year":"2013","unstructured":"Brandi G, de Rosa F, Agostini V, di Girolamo S, Andreone P, Bolondi L, Serra C, Sama C, Golfieri R, Gramenzi A, Cucchetti A, Pinna AD, Trevisani F, Biasco G, Italian Liver Cancer (ITA.LI.CA) Group (2013) Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist 18:1256\u20131257","journal-title":"Oncologist"},{"key":"2556_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rod\u00e9s J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421\u2013430","journal-title":"J Hepatol"},{"key":"2556_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208\u20131236","journal-title":"Hepatology"},{"key":"2556_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, RESORCE I (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56\u201366","journal-title":"Lancet"},{"key":"2556_CR7","doi-asserted-by":"publisher","first-page":"42499","DOI":"10.1038\/srep42499","volume":"7","author":"A Casadei Gardini","year":"2017","unstructured":"Casadei Gardini A, Foca F, Scartozzi M, Silvestris N, Tamburini E, Faloppi L, Brunetti O, Rudnas B, Pisconti S, Valgiusti M, Marisi G, Foschi FG, Ercolani G, Tassinari D, Cascinu S, Frassineti GL (2017) Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep 7:42499","journal-title":"Sci Rep"},{"key":"2556_CR8","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2009) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)"},{"key":"2556_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2217\/bmm.14.14","volume":"8","author":"G Cramarossa","year":"2014","unstructured":"Cramarossa G, Lee EK, Sivanathan L, Georgsdottir S, Lien K, Santos KD, Chan K, Emmenegger U (2014) A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. Biomark Med 8:893\u2013911","journal-title":"Biomark Med"},{"key":"2556_CR10","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino Jr","year":"1998","unstructured":"D\u2019Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265\u20132281","journal-title":"Stat Med"},{"key":"2556_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association","year":"2012","unstructured":"European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908\u2013943","journal-title":"J Hepatol"},{"key":"2556_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4236\/jct.2012.31010","volume":"3","author":"A Farrag","year":"2012","unstructured":"Farrag A (2012) Efficacy and toxicity of metronomic capecitabine in advanced hepatocellular carcinoma. J Cancer Ther 3:71\u201377","journal-title":"J Cancer Ther"},{"key":"2556_CR13","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","volume":"18","author":"RS Finn","year":"2012","unstructured":"Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18:2090\u20132098","journal-title":"Clin Cancer Res"},{"key":"2556_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.dld.2015.03.010","volume":"47","author":"A Granito","year":"2015","unstructured":"Granito A, Marinelli S, Terzi E, Piscaglia F, Renzulli M, Venerandi L, Benevento F, Bolondi L (2015) Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. Dig Liver Dis 47:518\u2013522","journal-title":"Dig Liver Dis"},{"key":"2556_CR15","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.3748\/wjg.v19.i28.4552","volume":"19","author":"SL He","year":"2013","unstructured":"He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC (2013) Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol 19:4552\u20134558","journal-title":"World J Gastroenterol"},{"key":"2556_CR16","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/hep.24644","volume":"54","author":"M Iavarone","year":"2011","unstructured":"Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Camm\u00e0 C, Colombo M; SOFIA (Sorafenib Italian Assessment) study group (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54:2055\u20132063","journal-title":"Hepatology"},{"key":"2556_CR17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva I, Waxman DJ, Lakka Klement G (2015) Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 358:100\u2013106","journal-title":"Cancer Lett"},{"key":"2556_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423\u2013436","journal-title":"Nat Rev Cancer"},{"key":"2556_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/annonc\/mdp010","volume":"20","author":"JO Lee","year":"2009","unstructured":"Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, Bang YJ (2009) Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol 20:1402\u20131407","journal-title":"Ann Oncol"},{"key":"2556_CR20","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.1097\/MD.0000000000000688","volume":"94","author":"IC Lee","year":"2015","unstructured":"Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH (2015) Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) 94:e688","journal-title":"Medicine (Baltimore)"},{"key":"2556_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360","journal-title":"Semin Liver Dis"},{"key":"2556_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/ijcp.12352","volume":"68","author":"R Lencioni","year":"2014","unstructured":"Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ (2014) GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib): second interim analysis. Int J Clin Pract 68:609\u2013617","journal-title":"Int J Clin Pract"},{"key":"2556_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390","journal-title":"N Engl J Med"},{"key":"2556_CR24","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","volume":"31","author":"JM Llovet","year":"2013","unstructured":"Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509\u20133516","journal-title":"J Clin Oncol"},{"key":"2556_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nrclinonc.2015.121","volume":"12","author":"JM Llovet","year":"2015","unstructured":"Llovet JM, Villanueva A, Lachenmayer A, Finn RS (2015) Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12:436","journal-title":"Nat Rev Clin Oncol"},{"key":"2556_CR26","doi-asserted-by":"publisher","first-page":"e11721","DOI":"10.5812\/hepatmon.11721","volume":"13","author":"S Marinelli","year":"2013","unstructured":"Marinelli S, Granito A, Piscaglia F, Renzulli M, Stagni A, Bolondi L (2013) Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. Hepat Mon 13:e11721","journal-title":"Hepat Mon"},{"key":"2556_CR27","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.dld.2016.06.037","volume":"48","author":"F Murer","year":"2016","unstructured":"Murer F, Pozzan C, Peserico G, Farinati F (2016) Capecitabine in advanced hepatocellular carcinoma. Dig Liver Dis 48:1260\u20131261","journal-title":"Dig Liver Dis"},{"key":"2556_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andr\u00e9 N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7:455\u2013465","journal-title":"Nat Rev Clin Oncol"},{"key":"2556_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/cncr.20368","volume":"101","author":"YZ Patt","year":"2004","unstructured":"Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101:578\u2013586","journal-title":"Cancer"},{"key":"2556_CR30","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.26586","volume":"58","author":"M Reig","year":"2013","unstructured":"Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, Llarch N, R\u00edos J, Ayuso C, Bruix J (2013) Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58:2023\u20132031","journal-title":"Hepatology"},{"key":"2556_CR31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jhep.2013.08.027","volume":"60","author":"YY Shao","year":"2014","unstructured":"Shao YY, Wu CH, Lu LC, Chan SY, Ma YY, Yen FC, Hsu CH, Cheng AL (2014) Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J Hepatol 60:313\u2013318","journal-title":"J Hepatol"},{"key":"2556_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23\u201344","journal-title":"Clin Ther"},{"key":"2556_CR33","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1245\/s10434-010-1148-3","volume":"17","author":"Y Xia","year":"2010","unstructured":"Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, Shen F, Yan Z, Wu M (2010) Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol 17:3137\u20133144","journal-title":"Ann Surg Oncol"},{"key":"2556_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2014.7189","volume":"312","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB, Chen LT (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312:57\u201367","journal-title":"JAMA"},{"key":"2556_CR35","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","volume":"16","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859\u2013870","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-017-2556-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2556-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:34:07Z","timestamp":1659058447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-017-2556-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["2556"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2556-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,16]]},"assertion":[{"value":"28 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Annual Grant from the Italian Ministry of Instruction, University and Research (MIUR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"The authors declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}